Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Domestic market blues... - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 28, 2003

    Cipla: Domestic market blues...

    Domestic pharma major, Cipla Ltd, has posted disappointing March numbers. The company has reported a marginal 2% dip in income from operations, but net profits shrunk by over 24% during the quarter. The company's operating margins nearly halved to just over 12% in 4QFY03.

    (Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
    Net Sales 3,943 3,882 -1.6% 14,005 15,724 12.3%
    Other Income 21 111 440.0% 284 258 -9.0%
    Expenditure 3,055 3,411 11.7% 10,961 12,561 14.6%
    Operating Profit (EBDIT) 888 471 -47.0% 3,044 3,164 3.9%
    Operating Profit Margin (%) 22.5% 12.1%   21.7% 20.1%  
    Interest 5 9 76.0% 21 16 -22.4%
    Depreciation 72 67 -6.7% 213 283 33.1%
    Profit before Tax 832 506 -39.2% 3,094 3,122 0.9%
    Tax 215 38 -82.1% 743 648 -12.8%
    Profit after Tax/(Loss) 617 467 -24.3% 2,351 2,475 5.3%
    Net profit margin (%) 15.7% 12.0%   16.8% 15.7%  
    No. of Shares 60.0 60.0   60.0 60.0  
    Diluted Earnings per share* 41.2 31.2   39.2 41.3  
    P/E Ratio         15.4  

    The company's domestic sales fell by 10% during the quarter (to about Rs 2 bn). The management seems to have attributed this to the slower domestic industry growth (about 2%-3%) during the quarter and also to the VAT worries owing to which stockists put off purchases until further clarity emerged on the issue. However, the dip in domestic sales was compensated by a 9% growth in export sales (to over Rs 1.9 bn). The export sales growth is very encouraging. The operating margin plummeted consequent to the flattish sales growth.

    In FY03, the company finished with just over 12% topline growth, with a marginal operating margin decline (can be attributed to the poor March quarter margins). Cipla managed to grow its bottomline by a staid 5% during the year. This growth was possible only because of a 12% dip in tax provisions, which came about owing to the tax benefits of the new Goa plant.

    Cost snapshot
    (Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
    (Increase)/decrease in stock in trade -444 -249 - -851 -787 -
    Raw material cost 2,002 2,235 11.6% 6,908 7,968 15.4%
    Staff cost 178 191 7.2% 633 729 15.2%
    Other expenses 1,318 1,234 -6.4% 4,272 4,651 8.9%
    Total expenditure 3,055 3,411 11.7% 10,961 12,561 14.6%

    The stock tanked today and touched new 52-week lows of Rs 565. Currently, at Rs 634 the stock trades at 15.4x FY03 earnings. We believe that the long term prospects of the company are good and are encouraged by the continuing export growth. However, the slowdown in the domestic markets is a cause for concern and may temper sentiment in the short term.



    Equitymaster requests your view! Post a comment on "Cipla: Domestic market blues...". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 11:24 AM



    Detailed Quarterly Results With Charts